Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Candidates Stream From Exelixis Discovery Platform

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm will decide whether - and how - to advance three late Phase I compounds in 2009; next big deal likely to focus on PI3/mTOR inhibitors.
Advertisement

Related Content

Best of the Blog: IN VIVO, May/June 2009
Best of the Blog: IN VIVO, May/June 2009
Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors
Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors
Love The One You’re With: BMS Pays Exelixis $240M Upfront In New Cancer Drug Deal
Love The One You’re With: BMS Pays Exelixis $240M Upfront In New Cancer Drug Deal
Exelixis Hopes To Avoid The Whole Capital Mess By Peddling Its Pipeline

Topics

Advertisement
UsernamePublicRestriction

Register

PS067132

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel